(6-甲氧基吡啶-2-基)甲胺盐酸盐 | 95851-89-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: (6-甲氧基吡啶-2-基)甲胺盐酸盐
• 英文名称: (6-Methoxypyridin-2-yl)methanamine hydrochloride
• 英文别名: (6-methoxypyridin-2-yl)methanamine;hydrochloride
• CAS: 95851-89-1
• 化学式: C7H11ClN2O
• 分子量: 174.63
• InChiKey: NHKBPLDFAZGMEO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.97
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  48.1
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (6-甲氧基吡啶-2-基)甲胺盐酸盐 、 氢溴酸 生成 6-aminomethyl-2(1H)-pyridone hydrobromide
  参考文献：
  名称：

  BRONN, WILLIAM R.

  摘要：

  DOI：
• 作为产物：
  描述：

  N-[(6-Methoxypyridin-2-yl)methyl]acetamide 、 盐酸 生成 (6-甲氧基吡啶-2-基)甲胺盐酸盐
  参考文献：
  名称：

  BRONN, WILLIAM R.

  摘要：

  DOI：

文献信息

• [EN] SUBSTITUTED HETEROCYCLIC DERIVATIVES<br/>[FR] DÉRIVÉS HÉTÉROCYCLIQUES SUBSTITUÉS
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014079850A1

  公开（公告）日：2014-05-30

  The present invention relates to compounds of general formula (I-1) or (I-2) wherein R1 is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; R1' is hydrogen, lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; with the proviso that both R1 and R1' may be simultaneously hydrogen, but only one of R1 and R1' is lower alkyl, lower alkoxy, halogen, O(CH2)2-lower akoxy, O(CH2)2N(CH3)2, or O(CH2)-morpholinyl; Het is a 5-or 6 membered heteroaryl group, wherein the heteroatom is selected from N, O or S; X is -CRR'-, -CRR'-NR'-, -C(O)-, -CH2-S-, -CH2-S(O)2-, CH2-O- or -CH2-CRR'-; R/R' are independently from each other hydrogen, lower alkyl, hydroxy or phenyl, or R and R' may form together with the carbon atom to which they are attached a cyclopropyl ring; R2 is lower alkyl, -C(O)O-lower alkyl, C3-6-cycloalkyl optionally substituted by lower alkyl or =O, bridged cyclohexyl or C3-6-cycloalkenyl, or is a 5-membered heteroaryl group, wherein the heteroatom is selected from N, O or S and which is optionally substituted by one or more lower alkyl, or is pyridinyl, optionally substituted by halogen or lower alkoxy; or is phenyl, optionally substituted by one or more R2', selected from halogen, cyano, S(O)2-lower alkyl, lower alkyl, lower alkyl substituted by halogen, lower alkoxy, lower alkoxy substituted by halogen or amino, or is benzo[1,3]dioxolyl, naphthyl, indolyl, benzo-isoxazolyl, 2,3-dihydro-1H-indenyl, optionally substituted by lower alkoxy or by an oxo group, or is 3,4-dihydro-2H- [1,4]oxazinyl, optionally substituted by an oxo group, or is a five or six membered heterocycloalkyl group; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof. The compounds may be used for the treatment or prophylaxis of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.

  本发明涉及通式（I-1）或（I-2）的化合物，其中R1为氢、较低烷基、较低烷氧基、卤素、O(CH2)2-较低烷氧基、O(CH2)2N(CH3)2或O(CH2)-吗啡啉基；R1'为氢、较低烷基、较低烷氧基、卤素、O(CH2)2-较低烷氧基、O(CH2)2N(CH3)2或O(CH2)-吗啡啉基；但要注意，R1和R1'中两者同时为氢，但只有一个为较低烷基、较低烷氧基、卤素、O(CH2)2-较低烷氧基、O(CH2)2N(CH3)2或O(CH2)-吗啡啉基；Het为5或6元杂芳基团，其中杂原子选自N、O或S；X为-CRR'-、-CRR'-NR'-、-C(O)-、-CH2-S-、-CH2-S(O)2-、CH2-O-或-CH2-CRR'-；R/R'独立地为氢、较低烷基、羟基或苯基，或R和R'可与它们连接的碳原子共同形成环丙基环；R2为较低烷基、-C(O)O-较低烷基、C3-6-环烷基（可选择地被较低烷基或=O取代）、桥环己基或C3-6-环烯基，或为5元杂芳基团，其中杂原子选自N、O或S，可选择地被一个或多个较低烷基取代，或为吡啶基，可选择地被卤素或较低烷氧基取代；或为苯基，可选择地被一个或多个来自卤素、氰基、S(O)2-较低烷基、较低烷基、被卤素取代的较低烷基、较低烷氧基、被卤素取代的较低烷氧基或氨基的R2'取代基，或为苯并[1,3]二氧杂环己基、萘基、吲哚基、苯并异噁唑基、2,3-二氢-1H-茚基，可选择地被较低烷氧基或氧羟基取代，或为3,4-二氢-2H-[1,4]噁唑基，可选择地被氧羟基取代，或为五元或六元杂环烷基团；或为药学上可接受的酸盐，或为外消旋混合物，或为其相应的对映体和/或光学异构体。这些化合物可用于治疗或预防精神分裂症、强迫性人格障碍、重性抑郁症、双相障碍、焦虑障碍、正常衰老、癫痫、视网膜退化、创伤性脑损伤、脊髓损伤、创伤后应激障碍、恐慌障碍、帕金森病、痴呆症、阿尔茨海默病、轻度认知障碍、化疗诱导的认知功能障碍、唐氏综合征、自闭症谱系障碍、听力损失、耳鸣、脊髓小脑性共济失调、肌萎缩侧索硬化、多发性硬化、亨廷顿病、中风、放射治疗、慢性压力、滥用神经活性药物，如酒精、阿片类药物、甲基苯丙胺、芬太尼和可卡因。
• Compound 2-acetamidomethyl-6-methoxy-pyridine
  申请人：Riker Laboratories, Inc.

  公开号：US04656285A1

  公开（公告）日：1987-04-07

  Certain substituted pyridine compounds are useful synthetic intermediates for preparing compounds of pharmaceutical interest. A synthetic process for using these intermediates is also described.

  某些取代吡啶化合物是制备药物化合物的有用合成中间体。还描述了使用这些中间体的合成过程。
• Metabolite
  申请人：Riker Laboratories, Inc.

  公开号：US04496734A1

  公开（公告）日：1985-01-29

  Synthetic 5-hydroxy-N-(6-oxo-2-piperidylmethyl)-2-(2,2,2-trifluoroethoxy) benzamide. The compound 5-hydroxy-N-(6-oxo-2-piperidylmethyl)-2-(2,2,2-trifluoroethoxy) benzamide is a metabolite of the antiarrhythmic agent 2,5-bis(2,2,2-trifluoroethoxy)-N-(2-piperidylmethyl)-benzamide.

  合成的5-羟基-N-(6-氧代-2-哌啶甲基)-2-(2,2,2-三氟乙氧基)苯甲酰胺。化合物5-羟基-N-(6-氧代-2-哌啶甲基)-2-(2,2,2-三氟乙氧基)苯甲酰胺是抗心律失常药物2,5-双(2,2,2-三氟乙氧基)-N-(2-哌啶甲基)-苯甲酰胺的代谢产物。
• Multi-step process for producing
  申请人：Riker Laboratories, Inc.

  公开号：US04824953A1

  公开（公告）日：1989-04-25

  Certain substituted pyridine compounds are useful synthetic intermediates for preparing compounds of pharmaceutical interest. A synthetic process for using these intermediates is also described.

  某些取代吡啶化合物是制备制药化合物的有用合成中间体。还描述了使用这些中间体的合成过程。
• Certain 6-benzamidomethyl-2(1H)-pyridone derivatives
  申请人：Riker Laboratories, Inc.

  公开号：US04555573A1

  公开（公告）日：1985-11-26

  Certain substituted pyridine compounds are useful synthetic intermediates for preparing compounds of pharmaceutical interest. A synthetic process for using these intermediates is also described.

  某些取代吡啶化合物是制备药物化合物的有用合成中间体。本文还描述了使用这些中间体的合成过程。